Neuropsychiatric symptoms such as agitation, aggression and psychosis are frequently found in patients with neurodegenerative disorders. These symptoms increase the already significant burden of neurodegenerative diseases and complicate diagnosis and disease management, yet effective diagnostics and treatments are lacking.

Towards the goal of reducing this burden, this symposium will review state-of-the-art methods in the diagnosis and behavioral and pharmaceutical management of neuropsychiatric symptoms across a spectrum of neurodegenerative diseases. Speakers, including the ADDF's Chief Science Officer Howard Fillit, MD, will address the challenges of defining neuropsychiatric symptoms in the context of neurodegenerative diseases, present findings regarding emerging diagnostic biomarkers and novel therapies, and discuss current estimates of associated societal and economic costs. A closing panel discussion will identify strategies to reduce these costs for patients, caregivers, and society.

This symposium is presented by The Brain and Behavior Discussion Group and co-organized by the Alzheimer's Drug Discovery Foundation, Mount Sinai Medical Center, and the New York Academy of Sciences.